title: [Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].
authors.affiliation: n2-koyama@hhc.eisai.co.jp
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Koyama
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tokunaga
authors.forename: Wakana
authors.initials: W
authors.lastname: Ogasawara
authors.forename: Miyuki
authors.initials: M
authors.lastname: Murakami
authors.forename: Yuji
authors.initials: Y
authors.lastname: Yamashita
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D017277:Drug Approval; D055808:Drug Discovery; D005260:Female; D005663:Furans / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D007262:Infusions, Intravenous; D007659:Ketones / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D009362:Neoplasm Metastasis; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D005663:Furans; D007659:Ketones; D050257:Tubulin Modulators; C490954:eribulin; D000095662:Polyether Polyketides